PRESENTATION

Q1 2021 — Presentation

Q1 2021PDF · 17 pages1.3 MB
Merck
Q1 2021 Earnings

-- 1 of 17 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
2
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive
the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 2 of 17 --

$12.1B
-1%
Q1 performance highlights
3
Advanced
the
pipeline
1. Growth rates exclude impact of foreign exchange
2. The GAAP to non-GAAP reconciliation is available in the Supplemental Tables to Merck’s Q1 2021 earnings release.
3. GAAP EPS =$1.25
4. Transaction closed April 1, 2021
Worldwide
sales
performance1
• 	Invested $2.4B in research and development, making
significant progress in advancing our pipeline and across
our key growth pillars
• 	Returned $1.6B to shareholders through dividends
• 	Executed value-enhancing business development,
including announcement of Pandion Therapeutics4
acquisition and collaboration with Gilead Sciences
$1.40
-9%
Non-GAAP
EPS
performance1
Created
shareholder
value
• 	FDA approved 2 filings in oncology and cardiovascular,
accepted 1 filing in chronic cough, and granted priority review
for 2 assets in oncology and vaccines
• 	In the EU, received 2 approvals and 1 CHMP positive opinion
for KEYTRUDA
• 	Received 2 approvals in oncology in China and Japan
• 	Presented data at SGO, ASCO GU, CROI and AACR
• 	Toplined results in oncology and HIV
• 	Advanced multiple assets into later stages of development in
oncology, HIV and vaccines

-- 3 of 17 --

Driving value for patients and shareholders by progressing our pipeline
Key regulatory milestones through April 29:
• 	In the U.S., the FDA approved KEYTRUDA in esophageal cancer (KN-590) and VERQUVO in chronic
heart failure (VICTORIA); accepted filing for gefapixant in chronic cough (COUGH-1 and COUGH-2);
and granted priority review for belzutifan in VHL-associated RCC and V114 in adults
• 	In the EU, received approval for expanded indications for KEYTRUDA in cHL (KN-204) and colorectal
cancer (KN-177), and received a CHMP positive opinion for KEYTRUDA in urothelial carcinoma (KN-
361)
• 	In China, received approval for KEYTRUDA Q6W dosing regimen for all approved indications
• 	In Japan, received approval for LENVIMA in thymic cancer
Key data presentations through April 29:
• 	Presented new data from KN-775/Study 309 in endometrial cancer at SGO, KN-581/Study 307 in RCC
at ASCO GU, and from multiple oncology studies at AACR including KEYLYNK-007 studying
KEYTRUDA+Lynparza in advanced solid tumors, KEYNOTE-555 studying subcutaneous
administration of KEYTRUDA, KEYNOTE-629 studying KEYTRUDA in cSCC, and data for intratumoral
KEYTRUDA+V937 (oncolytic virus) in advanced melanoma
• 	At CROI, presented data from broad HIV pipeline including a Phase 1 trial studying investigational
islatravir subdermal implant for the prevention of HIV-1, which will be moving into Phase 2 as a once
yearly implant
• 	Toplined results for Lynparza in early-stage breast cancer based on the pivotal OlympiA trial, for
KEYTRUDA in RCC based on KN-564 and for Phase 2 once-monthly oral islatravir in PrEP
• 	Advanced novel mechanism coformulations with pembrolizumab into Phase 3:
pembrolizumab+vibostolimab (TIGIT) in NSCLC and pembrolizumab+quavonlimab (CTLA-4) in RCC
• 	Advanced islatravir once-monthly oral into Phase 3 for the prevention of HIV, and MK-1654
(monoclonal antibody) into Phase 2/3 for RSV 4

-- 4 of 17 --

Oncology: continued strong growth
• 	KEYTRUDA sales of $3.9B increased 16% year-
over-year, driven by momentum in lung and
strong performance across indications
o 	In the U.S., sales of $2.2B driven by growth
across all key tumor types, including
continued leadership in lung, as well as
uptake in the Q6W dosing regimen
o 	Ex-U.S., 18% growth was driven by global
uptake in lung as well as RCC and H&N
• 	Lynparza sales increased 51%, with growth
driven by continued uptake in approved
indications
• 	Lenvima performance reflective of competition
in HCC and an unfavorable impact to revenue for
the recent NRDL listing in China
1. All growth rates exclude the impact of foreign exchange. 	5
1Q20 	1Q21
+16% YOY
KEYTRUDA Performance
1Q20 	1Q21
Lynparza Performance
+51% YOY
1Q20 	1Q21
Lenvima Performance
-1% YOY

-- 5 of 17 --

Vaccines: COVID-19 dynamics more than offset underlying demand
• 	GARDASIL sales of $917M negatively impacted
by timing of public sector purchases and timing
of shipments in China
o 	In the U.S., sales declined year-over-year
primarily due to public sector buying
patterns and impact from COVID-19 on
access to healthcare providers
o 	Ex-U.S., sales declined year-over-year,
driven by lower shipments in China and
negative impact from the pandemic,
particularly in Europe
• 	PNEUMOVAX sales of $171M reflect lower
demand due to COVID-19, partially offset by
higher volumes ex-U.S.
1. All growth rates exclude the impact of foreign exchange. 	6
1Q20 	1Q21
GARDASIL Performance
-20% YOY
1Q20 	1Q21
PNEUMOVAX Performance
-36% YOY

-- 6 of 17 --

Hospital: continued global recovery
1Q20 	1Q21
• 	BRIDION sales of $340M increased 11%
year-over-year, driven by higher demand
globally and increased elective surgery
procedures
• 	Continued uptake in PREVYMIS, driven by
ongoing launches
• 	Continued to build on long legacy in HIV
through collaboration with Gilead
1. All growth rates exclude the impact of foreign exchange.
+11% YOY
7
BRIDION Performance

-- 7 of 17 --

Animal Health: strong growth across innovative portfolio
• 	Animal Health sales increased 15% to $1.4B
o 	Companion Animal sales increased 24%,
driven by strength in parasiticides and
vaccines
o 	Livestock sales increased 9%, reflecting
increased international demand in
ruminant, poultry and swine, as well as
global demand for Animal Intelligence
products
1. All growth rates exclude the impact of foreign exchange. 	8
1Q20 	1Q21
+15% YOY
Animal Health Performance

-- 8 of 17 --

Global human health performance
United
States
Canada
Europe 2
Latin
America
Eastern Europe /
Middle East
Africa
Japan
+0%
China
Global
pharmaceutical
sales -3%1
$343M
-5%
-2% 	-14%
+14%
-2%
-8%
Asia Pacific
-6%
9
1. All growth rates exclude the impact of foreign exchange.
2. Europe primarily represents all European Union countries, the European Union accession markets and the United Kingdom.

-- 9 of 17 --

Q1 2021 financial results summary:
Growth offset by impact from COVID-19
Q1 2021 	Q1 2020 	Change Change
Ex-FX
Sales 	$12.1 	$12.1 	+0% 	-1%
GAAP Gross Margin 	69.6% 	72.5% 	-3% 	-3%
Non-GAAP Gross Margin 2 	75.7% 	76.5% 	-1% 	-1%
GAAP net income 1 	$3.2 	$3.2 	-1% 	-3%
Non-GAAP net income
that excludes certain items 1,2 	$3.6 	$3.9 	-8% 	-9%
GAAP EPS 	$1.25 	$1.26 	-1% 	-3%
Non-GAAP EPS that excludes
certain items 2 	$1.40 	$1.51 	-7% 	-9%
$ in billions, except EPS amounts
10
1. Net income attributable to Merck & Co., Inc.
2. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP. As previously disclosed, beginning in 2021, Merck changed the treatment of certain items for purposes of its non-GAAP reporting. Prior periods have been recast to
conform to the current presentation. For a description of the non-GAAP adjustments.

-- 10 of 17 --

Updated full-year 2021 guidance1
1. All estimates based on the assumption that the Organon business will be a part of Merck for all of 2021
2. GAAP Gross Margin Rate: Higher than 2020 by a low single-digit rate
3. GAAP Operating Expenses: Lower than 2020 by a mid-single-digit rate
4. GAAP Tax Rate: ~15.0% - 16.0%
5. The GAAP to non-GAAP reconciliation is available in Merck’s Q1 2021 earnings release
6. Growth rates reflective of recast of non-GAAP P&L presentation
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $51.8B to $53.8B
+8% to +12% (+6% to +10% ex-FX)
$51.8B to $53.8B
+8% to +12% (+6% to +10% ex-FX)
• 	Now assumes <2% positive FX impact
• 	Now assumes ~3% negative impact due
to COVID-19, particularly during the first
half of 2021
Non-GAAP
Gross Margin Rate 2 	~77.0% 	~76.0% • 	Slightly less than prior guidance as a
result of the impact of COVID-19
Non-GAAP
Operating Expenses3
Increase by high single to low
double-digit rate
Increase by mid-to-high
single-digit rate
• 	Expense management helping to offset
spend on COVID-19 research programs
Other (Income) / Expense 	~$400M of expense 	~$400M of expense 	• 	No change
Tax Rate 4 	~15.0-16.0% 	~15.0-16.0% 	• 	No change
Shares Outstanding 	~2.53B 	~2.53B 	• 	No change
GAAP EPS 5 	$5.52 to $5.72 	$5.05 to $5.25
Non-GAAP EPS 5,6 	$6.48 to $6.68
+12% to +15% (+9% to +12% ex-FX)
$6.48 to $6.68
+12% to +15% (+9% to +12% ex-FX) • 	Now assumes <3% positive FX impact
11

-- 11 of 17 --

Accelerating towards the spinoff of Organon & Co.
12
May 3
Merck Investor
Day featuring
Organon
June 2
Expected
completion of
spinoff
June 3
Commencement
of trading in
Organon stock
(OGN) on NYSE
April 8
Pricing of
Organon
senior notes
March 17
Filing of
Form 10
March 30
Merck announces
acquisition of
Alydia Health on
behalf of Organon 1
Advancements
Upcoming milestones
1. Expected to close after Organon has spun off from Merck as a standalone publicly traded company .

-- 12 of 17 --

Balanced approach to capital allocation:
Investing in the business and creating value for shareholders
Capital Investments
2020 to 2024
>$ 20B
Over 5 years, including expanding manufacturing
capacity for Oncology, Vaccines, and Animal
Health. Includes >$10B in the U.S.
Over the Past 12 Months
$8.2
$4.8
$6.3
$7.6
$0
$2
$4
$6
$8
$10
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
$10.6
Billions
ORDER OF
PRIORITY
Commitment to the Dividend
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44 $2.60
$1.40
$1.70
$2.00
$2.30
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021E
Dollars per share
+11% 	+2% 	+2% +2% 	+2% 	+2%
+11%
13
+15%
• 	$9.5 billion invested in R&D ($8.2 billion after-tax)
• 	$7.6 billion spent on business development
o 	Including acquisition of VelosBio and strategic oncology
collaborations with Seagen
o 	In addition, announced Pandion Therapeutics
acquisition1 and HIV collaboration with Gilead
• 	$6.3 billion in dividends - remain committed to the dividend,
which increased 7% in 2021
Balanced Capital Allocation to Invest in Growth While
Returning Cash to Shareholders Over Past 12 Months
+7%
1. Transaction closed April 1, 2021.

-- 13 of 17 --

Merck has actively supplemented its pipeline and portfolio with
strategic business development
14
Oncology 	Cardiovascular,
Neurosciences & Other
Animal Health
Bolt-on acquisitions
Strategic
collaborations
& licensing

-- 14 of 17 --

Expansion of HIV development program
through collaboration with Gilead
15
Once-Monthly Oral
islatravir
Once-Yearly Implant
islatravir
Once-Daily Oral
islatravir + doravirine
Once-Weekly Oral
islatravir + MK-8507
Long-Acting Oral
islatravir + lenacapavir
Long-Acting Injectable
islatravir + lenacapavir
Internal treatment
development program
Treatment
development program
in collaboration
with Gilead
Internal PrEP
development program
Islatravir as the foundation of our broad HIV development program
1. Islatravir and lenacapavir are investigational compounds.

-- 15 of 17 --

Creating long-term value for patients, employees and shareholders
Anchored by our deep bench of talent
and commitment to our mission
Next 5 Years
Strong execution driving
sustainable revenue growth,
meaningful margin expansion and
accelerated bottom-line growth
5-10 Years
Rich pipeline addressing
areas of high unmet need to
drive performance over the
next 5 to 10 years
10+ Years
Revitalized discovery efforts and
increased expertise in biology to
deliver ongoing scientific
breakthroughs for decades to come
16

-- 16 of 17 --

Continuing to make progress on our ESG commitments
Access to
Health
Employees
Environmental
Sustainability
Ethics and
Transparency
Earning trust and confidence of stakeholders is critical for a company in the business of marketing and selling medicines and
vaccines
• 	Demonstrated commitment to transparency through disclosures about our business and how we operate, including issuing a multi-year report about
pricing practices
• 	Work with broad range of stakeholders to help develop and advance innovative financing and solutions that address the needs of patients
• 	Integrating the SDGs into our reporting to demonstrate our commitment to sustainable development
Executing an environmental sustainability strategy to take advantage of opportunities to reduce environmental impact
across operations and supply chain
• 	Featuring energy-conservation and water-use-reduction initiatives
• 	Reducing environmental impacts as evidenced by an EPA Green Chemistry Challenge Award four years running (seven awards overall)
• 	Purchasing electricity from renewable energy sources to reduce greenhouse gas emissions, including the launch of our first large wind virtual
power purchase agreement
• 	Collaborating with suppliers and customers to address shared needs and interests in environmentally beneficial ways
Fostering diverse and gender-balanced workforce essential to performance as a research-intensive company and to attracting most
talented scientists
• 	Offering numerous programs to engage employees and promote positive work environment (including female mentorship by female Board members)
• 	Partnering with Year Up, a nonprofit that enables low-income young adults of color to move from minimum wage to meaningful careers in just one year
• 	Increase in 2019 in women on our Board (33%), in executive roles (36%), and in management roles (43%)
• 	Recognized as a 2020 best place to work for LGBTQ equality by the Human Rights Campaign (HRC) Foundation
• 	Identified by the American Indian Science and Engineering Society (AISES) as a 50 Top STEM Workplaces for Indigenous STEM Professionals
Increasing access to health to advance Merck’s efforts to serve more patients
• 	History of making medicines and vaccines accessible and affordable through responsible pricing practices
• 	Implemented refreshed Access to Health Guiding Principles to ensure we continue to fulfill our commitment to access by focusing on the most critical issues
• 	Reaching more than 13 million women worldwide through Merck for Mothers, a $500 million initiative
• 	Through our 30+ year old MECTIZAN® Donation Program, eliminated river blindness in 4 Latin American countries and in parts of 6 African countries so far, and
eliminated lymphatic filariasis in 3 countries in Africa and the Middle East
• 	Thanks to the commitment of many collaborators across multiple sectors, ERVEBO, Merck’s vaccine for the prevention of disease caused by Zaire ebolavirus in
adults, is now registered in nine African countries at high risk of Ebola (with additional African country registrations pending review). These registrations followed
WHO prequalification, conditional approval in the EU, and licensure in the United States.
17
Please find our 2019/2020 Corporate Responsibility Report here.

-- 17 of 17 --